|
Eat and be healthy: nutritional status in myelodysplastic syndromes
|
Jul 2020
|
Leukemia & Lymphoma
|
myelodysplastic syndromes (MDS)
|
|
Association of provider experience and clinical outcomes in patients with myelodysplastic syndromes receiving hypomethylating agents
|
Oct 2019
|
Leukemia & Lymphoma
|
myelodysplastic syndromes (MDS)
|
|
Phase II study of the clinical efficacy and safety of tosedostat in patients with myelodysplastic syndromes (MDS) after failure of hypomethylating agent-based therapy
|
Oct 2020
|
Leukemia & Lymphoma
|
myelodysplastic syndromes (MDS)
|
|
Consensus minimum hemoglobin level above which patients with myelodysplastic syndromes can safely forgo transfusions
|
Jul 2020
|
Leukemia & Lymphoma
|
myelodysplastic syndromes (MDS)
|
|
Clonal evolution in aplastic anemia: failed tumor surveillance or maladaptive recovery?
|
Jun 2023
|
Leukemia & Lymphoma
|
aplastic anemia
|
|
Clonal dynamics of aplastic anemia/paroxysmal nocturnal hemoglobinuria
|
Dec 2019
|
Leukemia & Lymphoma
|
aplastic anemia
|
|
Venetoclax and hypomethylating agent therapy in high risk myelodysplastic syndromes: a retrospective evaluation of a real-world experience
|
Nov 2020
|
Leukemia & Lymphoma
|
myelodysplastic syndromes (MDS)
|
|
Raising the bar for lower-risk myelodysplastic syndromes
|
Apr 2023
|
Leukemia & Lymphoma
|
myelodysplastic syndromes (MDS)
|
|
Cardiac and genetic predictors of cardiovascular risk in patients with myelodysplastic syndromes
|
May 2019
|
Leukemia & Lymphoma
|
myelodysplastic syndromes (MDS)
|
|
Fit older adults with advanced myelodysplastic syndromes: who is most likely to benefit from transplant?
|
Nov 2020
|
Leukemia & Lymphoma
|
myelodysplastic syndromes (MDS)
|
